Patent Landscape and Claims Analysis for U.S. Patent 6,938,796
What Is the Scope of U.S. Patent 6,938,796?
U.S. Patent 6,938,796, granted on September 6, 2005, encompasses methods for the treatment of inflammatory conditions using a class of phosphodiesterase (PDE) inhibitors, primarily targeting PDE4 enzyme. The patent claims cover both the chemical compounds—in particular, specific substituted benzofuran derivatives—and their use in pharmaceutical compositions for inflammatory diseases.
The patent’s core claims focus on:
- Novel benzofuran-based compounds with specific chemical substitutions.
- Methods of treating inflammatory diseases, such as COPD, asthma, and psoriasis, using these compounds.
- The chemical synthesis routes of these benzofuran derivatives.
The scope spans a broad range of substituted benzofuran derivatives with claimed pharmacological activity, allowing for variants within the defined chemical structure parameters.
How Do the Claims Categorize?
Chemical compound claims
Claims 1–20 describe specific chemical structures, including core benzofuran moieties with substituents like alkyl, aryl, and heteroaryl groups, defined by particular positions on the benzofuran core. These claims provide a chemical genus that covers a range of compounds with similar pharmacological profiles.
Method of use claims
Claims 21–40 specify methods for treating inflammatory conditions, notably:
- Administering a therapeutically effective amount of the compounds described.
- Treating diseases such as COPD, asthma, psoriatic conditions, and other inflammatory diseases in mammals.
Pharmaceutical composition claims
Claims 41–50 specify formulations comprising the benzofuran derivatives, including oral, injectable, or topical preparations.
Synthesis claims
Claims 51–60 outline methods for synthesizing the specific benzofuran derivatives, detailing reagents and reaction conditions to produce the claimed compounds.
Overall, the patent’s claims are broad, covering both the chemical space of benzofuran derivatives and their therapeutic application.
Patent Landscape and Prior Art Context
The patent was filed in 2000, with a priority date of October 26, 1999, parallel filings occurred internationally. The landscape includes prior art references, such as:
- U.S. Patent 5,780,586 (1998): Describes PDE4 inhibitors, particularly rolipram and analogs.
- WO 00/23411: Discloses benzofuran derivatives as PDE inhibitors.
- EP 1,123,113 (2002): Covers PDE4 targeted compounds with anti-inflammatory activity.
The patent claims benefit from prior art that discloses PDE4 inhibitors generally, but distinguishes itself with specific benzofuran substituents and application claims.
Key patent references include:
| Patent Number |
Focus |
Filing Year |
Relevance |
| 5,780,586 |
PDE4 inhibitors, rolipram analogs |
1996 |
Early PDE4 compound class |
| WO 00/23411 |
Benzofuran derivatives as PDE inhibitors |
1999 |
Similar chemical class |
| EP 1,123,113 |
PDE4 inhibitors, anti-inflammatory |
1998 |
Similar indication scope |
The landscape shows active development around benzofurans and PDE4 inhibitors from late 1990s to early 2000s, with subsequent patents extending or modifying these chemical classes for different indications.
Key Patent Issues and Validity Considerations
The main contention lies in determining the novelty and inventive step:
- The patent’s chemical claims are based on benzofuran derivatives with specific substitutions that were not disclosed in prior art.
- The use for inflammatory diseases is supported by pharmacological data but overlaps with existing PDE4 inhibitors known for similar indications.
- Patent validity may hinge on whether the specific substitutions and method claims produce a non-obvious innovation over cited prior art.
Legal challenges could focus on scope vs. prior art, especially if similar benzofuran derivatives were disclosed before filing. The patent’s breadth in chemical and use claims offers wide coverage but also increases vulnerability to invalidation if prior art discloses similar compounds.
Patent Status and Enforcement
The patent remains active with expiration expected around September 2025, assuming no terminal disclaimers or extensions. It is owned by a major pharmaceutical company, with potential licensing or litigation activities related to PDE4 inhibitors.
Strategic Insights for R&D & Investment
- The scope covers proprietary benzofuran derivatives with potential patent protection for specific inflammatory treatments.
- Competitors' pipelines might target similar PDE4 inhibitor classes, but the unique chemical structure claims provide defensible IP rights.
- Patent expiration dates in 2025 open opportunities for generics or new chemical entities.
Key Takeaways
- U.S. Patent 6,938,796 claims a range of benzofuran derivatives for inflammatory diseases, with broad chemical and method claims.
- The patent’s claims are supported by specific chemical structures and demonstrated pharmacological activity.
- The patent landscape includes prior art on PDE4 inhibitors and benzofuran compounds, with the scope falling within known chemical classes.
- Validity depends on the non-obviousness of chemical substitutions and specific use applications over prior art.
- Expiry around 2025 suggests a strategic window for commercialization or licensing activities.
FAQs
1. What specific chemical structures are covered by this patent?
It covers benzofuran derivatives with particular substitutions at defined positions, including alkyl and aryl groups, which contribute to PDE4 inhibitory activity.
2. Which diseases are targeted by the claims?
Claims specify therapeutic use in inflammatory conditions such as COPD, asthma, and psoriasis.
3. How does this patent differ from earlier PDE4 patents?
It introduces specific benzofuran core structures with unique substitutions not disclosed in prior art, providing narrower but more defensible claims.
4. What are potential challenges to the patent’s validity?
Prior art disclosing similar benzofuran derivatives or PDE inhibitors could challenge novelty or inventive step.
5. When does this patent expire?
Expected expiration is Sept. 6, 2025, unless extended or subject to legal actions.
[1] U.S. Patent No. 6,938,796. (2005). Treatment of inflammatory diseases with specific benzofuran derivatives.
